- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT06820463
Un estudio para evaluar los eventos adversos y la eficacia de los intravenosos (iv) de telisotuzumab adizuteecan en combinación con oxaliplatino IV, fluorouracilo, ácido folínico/leucovorina, bevacizumab, panitumumab en participantes adultos con cáncer colorrectal metastático (AndroMETa-CRC)
Un estudio de protocolo maestro de fase 2, abierto, aleatorizado, de protocolo maestro para evaluar la seguridad y la eficacia de múltiples combinaciones de tratamiento con telisotuzumab adizutecan en sujetos con cáncer colorrectal metastásico
CRC is the third most common type of cancer diagnosed worldwide with developed countries at highest risk. The purpose of this study is to assess adverse events and change in disease activity when telisotuzumab adizutecan is given in combination with oxaliplatin, fluorouracil (5FU), leucovorin (LV) (FOLFOX), and bevacizumab or panitumumab.
Telisotuzumab adizutecan is an investigational drug being developed for the treatment of mCRC. Fluorouracil and leucovorin are drugs approved for the treatment of mCRC. This study will be divided into two stages, with the first stage treating participants with increasing doses of telisotuzumab adizutecan with FOLFOX and bevacizumab or 5FU/LV and panitumumab until the dose reached is tolerable and expected to be efficacious. Participants will then be randomized into 3 groups called treatment arms where one group will receive one of two optimized doses of telisotuzumab adizutecan from the dose escalation phase with FOLFOX and bevacizumab or 5FU/LV and panitumumab, or a comparator of FOLFOX and bevacizumab or panitumumab. Approximately 390 adult participants with mCRC will be enrolled in the study in 100 sites worldwide.
In the dose escalation stage participants will be treated with increasing intravenous (IV) doses of telisotuzumab adizutecan with FOLFOX and bevacizumab or 5FU/LV and panitumumab until the dose reached is tolerable and expected to be efficacious. In the dose optimization stage participants will be receive FOLFOX or receive 5FU/LV, but with one of two optimized doses of telisotuzumab adizutecan, or a comparator of FOLFOX and bevacizumab/pantitumumab. The study will run for a duration of approximately 6 years.
There may be higher treatment burden for participants in this trial compared to their standard of care. Participants will attend regular visits during the study at an approved institution (hospital or clinic). The effect of the treatment will be frequently checked by medical assessments, blood tests, questionnaires and side effects.
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Tipo de estudio
Inscripción (Estimado)
Fase
- Fase 2
Contactos y Ubicaciones
Estudio Contacto
- Nombre: ABBVIE CALL CENTER
- Número de teléfono: 844-663-3742
- Correo electrónico: abbvieclinicaltrials@abbvie.com
Ubicaciones de estudio
-
-
New South Wales
-
Sydney, New South Wales, Australia, 2109
- Reclutamiento
- Macquarie University /ID# 271514
-
-
Queensland
-
South Brisbane, Queensland, Australia, 4101
- Reclutamiento
- Mater Misericordiae /ID# 270694
-
Contacto:
- Site Coordinator
- Número de teléfono: +61731632341
-
-
South Australia
-
Woodville South, South Australia, Australia, 5011
- Reclutamiento
- The Queen Elizabeth Hospital /ID# 270693
-
-
Victoria
-
Heidelberg, Victoria, Australia, 3084
- Reclutamiento
- Austin Health /ID# 270692
-
-
Western Australia
-
Nedlands, Western Australia, Australia, 6009
- Reclutamiento
- One Clinical Research /ID# 270695
-
-
-
-
-
Salzburg, Austria, 5020
- Reclutamiento
- Landeskrankenhaus Salzburg-Universitaetsklinikum der PMU (LKH) /ID# 268874
-
Vienna, Austria, 1090
- Reclutamiento
- Medizinische Universitaet Wien /ID# 268872
-
-
Styria
-
Graz, Styria, Austria, 8010
- Reclutamiento
- Medizinische Universitaet Graz /ID# 268876
-
-
-
-
-
São Paulo, Brasil, 04014-002
- Reclutamiento
- Nucleo De Pesquisa Clinica Da Rede Sao Camilo /ID# 272311
-
São Paulo, Brasil, 01401-002
- Reclutamiento
- Instituto D Or De Pesquisa E Ensino - Regional Sao Paulo /ID# 270546
-
-
Estado de Bahia
-
Salvador, Estado de Bahia, Brasil, 41253-190
- Reclutamiento
- Hospital Sao Rafael /ID# 271681
-
-
Rio Grande do Sul
-
Ijuí, Rio Grande do Sul, Brasil, 98700-000
- Reclutamiento
- Oncosite - Centro de Pesquisa Clinica em Oncologia /ID# 270147
-
-
São Paulo
-
Barretos, São Paulo, Brasil, 14784-400
- Reclutamiento
- Hospital De Amor /ID# 271874
-
São José do Rio Preto, São Paulo, Brasil, 15090-000
- Reclutamiento
- Fundacao Faculdade Regional de Medicina de Sao Jose do Rio Preto /ID# 271651
-
-
-
-
Alberta
-
Calgary, Alberta, Canadá, T2N 5G2
- Reclutamiento
- Arthur J.E Child Comprehensive Cancer Centre /ID# 269809
-
Edmonton, Alberta, Canadá, T6G 1Z2
- Reclutamiento
- Cross Cancer Institute. /ID# 272711
-
-
Ontario
-
London, Ontario, Canadá, N6A 5W9
- Reclutamiento
- London Health Sciences Centre - Victoria Hospital & Children's Hospital /ID# 270680
-
Toronto, Ontario, Canadá, M5G 2M9
- Reclutamiento
- Princess Margaret Cancer Centre /ID# 268715
-
-
Quebec
-
Montreal, Quebec, Canadá, H1T 2M4
- Reclutamiento
- Universite de Montreal - Hopital Maisonneuve-Rosemont /ID# 271368
-
-
-
-
-
Brno, Chequia, 656 53
- Reclutamiento
- Masarykuv onkologicky ustav v Brne /ID# 268779
-
Hradec Králové, Chequia, 500 05
- Reclutamiento
- Fakultni nemocnice Hradec Kralove - Sokolska /ID# 268773
-
-
Praha 17
-
Prague, Praha 17, Chequia, 128 00
- Reclutamiento
- Vseobecna Fakultni nemocnice v Praze /ID# 268775
-
-
Praha 5
-
Prague, Praha 5, Chequia, 150 06
- Reclutamiento
- Fakultni nemocnice Motol a Homolka /ID# 268776
-
-
Praha, Hlavni Mesto
-
Prague, Praha, Hlavni Mesto, Chequia, 140 59
- Reclutamiento
- Fakultni Thomayerova nemocnice /ID# 269632
-
-
-
-
-
Barcelona, España, 08035
- Reclutamiento
- Hospital Universitario Vall de Hebron /ID# 270191
-
Madrid, España, 28027
- Reclutamiento
- Clinica Universidad de Navarra - Madrid /ID# 269754
-
Madrid, España, 28046
- Reclutamiento
- Hospital Universitario La Paz /ID# 269730
-
Valencia, España, 46010
- Reclutamiento
- Hospital Clinico Universitario de Valencia /ID# 269805
-
-
Cantabria
-
Santander, Cantabria, España, 39008
- Reclutamiento
- Hospital Universitario Marques de Valdecilla /ID# 269732
-
-
Navarre
-
Pamplona, Navarre, España, 31008
- Reclutamiento
- Clinica Universidad de Navarra - Pamplona /ID# 269753
-
-
-
-
California
-
Duarte, California, Estados Unidos, 91010
- Reclutamiento
- City of Hope National Medical Center /ID# 270255
-
Santa Monica, California, Estados Unidos, 90404
- Reclutamiento
- UCLA - Santa Monica /ID# 270621
-
-
Connecticut
-
New Haven, Connecticut, Estados Unidos, 06510
- Reclutamiento
- Yale New Haven Hospital /ID# 270565
-
-
Florida
-
Orlando, Florida, Estados Unidos, 32803
- Reclutamiento
- AdventHealth Orlando /ID# 270789
-
-
Georgia
-
Marietta, Georgia, Estados Unidos, 30060
- Reclutamiento
- Northwest Georgia Oncology Centers /ID# 270245
-
-
Illinois
-
Chicago, Illinois, Estados Unidos, 60637
- Reclutamiento
- University of Chicago Medical Center /ID# 271688
-
Hinsdale, Illinois, Estados Unidos, 60521
- Reclutamiento
- Hope And Healing Cancer Services /ID# 271562
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02215
- Reclutamiento
- Dana-Farber Cancer Institute /ID# 270624
-
-
Michigan
-
Ann Arbor, Michigan, Estados Unidos, 48109-5000
- Reclutamiento
- University Of Michigan /ID# 270790
-
-
Missouri
-
Kansas City, Missouri, Estados Unidos, 64111
- Reclutamiento
- Saint Lukes Hospital of Kansas City /ID# 270633
-
-
Nebraska
-
Omaha, Nebraska, Estados Unidos, 68130
- Reclutamiento
- Nebraska Cancer Specialists - Omaha - Wright Street /ID# 271646
-
-
North Carolina
-
Chapel Hill, North Carolina, Estados Unidos, 27514
- Reclutamiento
- University of North Carolina at Chapel Hill /ID# 267786
-
-
Ohio
-
Cincinnati, Ohio, Estados Unidos, 45245
- Reclutamiento
- Oncology Hematology Care - Eastgate /ID# 271493
-
-
Texas
-
Austin, Texas, Estados Unidos, 78705
- Reclutamiento
- Texas Oncology - Austin Midtown /ID# 271354
-
Webster, Texas, Estados Unidos, 77598
- Reclutamiento
- Texas Oncology - Deke Slayton Cancer Center /ID# 271355
-
-
Virginia
-
Fairfax, Virginia, Estados Unidos, 22031
- Reclutamiento
- Virginia Cancer Specialists - Fairfax /ID# 271351
-
-
Washington
-
Seattle, Washington, Estados Unidos, 98109
- Reclutamiento
- University Of Washington /ID# 271298
-
-
-
-
-
Paris, Francia, 75015
- Reclutamiento
- Hopital Europeen Georges Pompidou /ID# 270224
-
-
Hauts-de-France
-
Lille, Hauts-de-France, Francia, 59037
- Reclutamiento
- Centre Hospitalier Regional Universitaire de Lille - Hopital Claude Huriez /ID# 270222
-
-
New Aquitaine
-
Poitiers, New Aquitaine, Francia, 86021
- Reclutamiento
- Centre Hospitalier Universitaire de Poitiers /ID# 270225
-
-
Pays de la Loire Region
-
Nantes, Pays de la Loire Region, Francia, 44000
- Reclutamiento
- Centre Hospitalier Universitaire de Nantes, Hotel Dieu -HME /ID# 270221
-
-
Île-de-France Region
-
Paris, Île-de-France Region, Francia, 75013
- Reclutamiento
- Hopital Pitie Salpetriere /ID# 270220
-
-
-
-
-
Thessaloniki, Grecia, 54639
- Reclutamiento
- Theagenio Cancer Hospital /ID# 269640
-
-
Attica
-
Chaïdári, Attica, Grecia, 12462
- Reclutamiento
- University General Hospital Attikon /ID# 268555
-
Nea Kifissia, Attica, Grecia, 14564
- Reclutamiento
- General Oncology Hospital of Kifisia Agioi Anargyroi /ID# 268762
-
Piraeus, Attica, Grecia, 18547
- Reclutamiento
- Metropolitan Hospital /ID# 269636
-
-
Thessaloniki
-
Panórama, Thessaloniki, Grecia, 55236
- Reclutamiento
- St. Luke's Hospital /ID# 269963
-
-
-
-
-
Haifa, Israel, 3109601
- Reclutamiento
- Rambam Health Care Campus- Haifa /ID# 268006
-
Jerusalem, Israel, 9103102
- Reclutamiento
- Shaare Zedek Medical Center /ID# 268009
-
Jerusalem, Israel, 91120
- Reclutamiento
- Hadassah Medical Center-Hebrew University /ID# 268007
-
-
Central District
-
Petah Tikva, Central District, Israel, 4941492
- Reclutamiento
- Rabin Medical Center. /ID# 268008
-
-
Tel Aviv
-
Tel Aviv, Tel Aviv, Israel, 6423906
- Reclutamiento
- Tel Aviv Sourasky Medical Center /ID# 268010
-
-
-
-
Milano
-
Milan, Milano, Italia, 20162
- Reclutamiento
- ASST Grande Ospedale Metropolitano Niguarda /ID# 269142
-
Contacto:
- Site Coordinator
- Correo electrónico: ctu.oncologia@ospedaleniguarda.it
-
-
Napoli
-
Naples, Napoli, Italia, 80138
- Reclutamiento
- Azienda Ospedaliera Universitaria Luigi Vanvitelli /ID# 269191
-
-
-
-
Aichi-ken
-
Nagoya, Aichi-ken, Japón, 464-8681
- Reclutamiento
- Aichi Cancer Center /ID# 270113
-
-
Chiba
-
Kashiwa-shi, Chiba, Japón, 277-8577
- Reclutamiento
- National Cancer Center Hospital East /ID# 270114
-
-
Kanagawa
-
Kawasaki-shi, Kanagawa, Japón, 216-8511
- Reclutamiento
- St Marianna University School Of Medicine /ID# 270111
-
-
Miyagi
-
Sendai, Miyagi, Japón, 980-8574
- Reclutamiento
- Tohoku University Hospital /ID# 270966
-
-
Tokyo
-
Chuo-Ku, Tokyo, Japón, 104-0045
- Reclutamiento
- National Cancer Center Hospital /ID# 270112
-
-
-
-
-
Rio Piedras, Puerto Rico, 00935
- Reclutamiento
- Pan American Center for Oncology Trials - Rio Piedras /ID# 268809
-
San Juan, Puerto Rico, 00917-5022
- Reclutamiento
- Puerto Rico Medical Research Center /ID# 268825
-
-
-
-
-
Manchester, Reino Unido, M20 4BX
- Reclutamiento
- The Christie NHS Foundation Trust - Christie Hospital /ID# 271561
-
-
Greater London
-
London, Greater London, Reino Unido, E1 2ES
- Reclutamiento
- Barts Health NHS Trust /ID# 271189
-
-
Oxfordshire
-
Oxford, Oxfordshire, Reino Unido, OX3 9DU
- Reclutamiento
- Oxford University Hospitals Nhs Foundation Trust /ID# 272486
-
-
Surrey
-
Sutton, Surrey, Reino Unido, SM2 5PT
- Reclutamiento
- The Royal Marsden - Sutton /ID# 271172
-
-
West Midlands
-
Birmingham, West Midlands, Reino Unido, B9 5SS
- Reclutamiento
- Heartlands Hospital - University Hospitals Birmingham /ID# 271178
-
-
-
-
-
Kaohsiung City, Taiwán, 807
- Reclutamiento
- Kaohsiung Medical University Chung-Ho Memorial Hospital /ID# 269724
-
Kaohsiung City, Taiwán, 833
- Reclutamiento
- Kaohsiung Chang Gung Memorial Hospital /ID# 269726
-
Tainan, Taiwán, 704
- Reclutamiento
- National Cheng Kung University Hospital /ID# 270835
-
Taipei, Taiwán, 112
- Reclutamiento
- Taipei Veterans General Hospital /ID# 269718
-
Taipei, Taiwán, 100
- Reclutamiento
- National Taiwan University Hospital /ID# 269717
-
Taoyuan City, Taiwán, 333
- Reclutamiento
- Linkou Chang Gung Memorial Hospital /ID# 269725
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria:
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
- Laboratory values meeting the criteria within the protocol.
- Has measurable disease per response evaluation criteria in solid tumors (RECIST) v1.1.
Exclusion Criteria:
- Prior systemic regimen containing c-Met targeting agent(s) (e.g., antibody, antibody drug conjugate, bispecific) and/or any topoisomerase inhibitor(s) (e.g., irinotecan).
- History of other malignancies within 5 years prior to screening, except for malignancies with a negligible risk of metastasis or death.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Ninguno (etiqueta abierta)
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Substudy 1: Dose Escalation Telisotuzumab Adizutecan
Participants will receive various doses of telisotuzumab adizutecan in combination with a fixed dose of fluorouracil, leucovorin, and oxaliplatin (FOLFOX) and bevacizumab as part of the approximately 6 year study duration. |
Intravenous (IV) Infusion IV Infusion IV Infusion; IV Injection IV Infusion IV Infusion; IV Injection |
|
Experimental: Substudy 1: Dose Expansion Telisotuzumab Adizutecan High Dose
Participants will receive the high dose of telisotuzumab adizutecan determined in the dose expansion arm in combination with a fixed dose of FOLFOX and bevacizumab as part of the approximately 6 year study duration. |
Intravenous (IV) Infusion IV Infusion IV Infusion; IV Injection IV Infusion IV Infusion; IV Injection |
|
Experimental: Substudy 1: Dose Expansion Telisotuzumab Adizutecan Low Dose
Participants will receive the low dose of telisotuzumab adizutecandetermined in the dose expansion arm in combination with a fixed dose of FOLFOX and bevacizumab as part of the approximately 6 year study duration. |
Intravenous (IV) Infusion IV Infusion IV Infusion; IV Injection IV Infusion IV Infusion; IV Injection |
|
Experimental: Substudy 1: Dose Expansion Compatator
Participants will receive a fixed dose of FOLFOX and bevacizumab as part of the approximately 6 year study duration. |
IV Infusion IV Infusion; IV Injection IV Infusion IV Infusion; IV Injection |
|
Experimental: Substudy 2: Dose Escalation Telisotuzumab Adizutecan
Participants will receive various doses of telisotuzumab adizutecan in combination with a fixed dose of fluorouracil (5-FU) and leucovorin (LV) and panitumumab as part of the approximately 6 year study duration. |
Intravenous (IV) Infusion IV Infusion; IV Injection IV Infusion; IV Injection IV Infusion |
|
Experimental: Substudy 2: Dose Expansion Telisotuzumab Adizutecan High Dose
Participants will receive the high dose of telisotuzumab adizutecan determined in the dose expansion arm in combination with a fixed dose of 5-FU/LV and panitumumab as part of the approximately 6 year study duration. |
Intravenous (IV) Infusion IV Infusion; IV Injection IV Infusion; IV Injection IV Infusion |
|
Experimental: Substudy 2: Dose Expansion Telisotuzumab Adizutecan Low Dose
Participants will receive the low dose of telisotuzumab adizutecan determined in the dose expansion arm in combination with a fixed dose of 5-FU/LV and panitumumab as part of the approximately 6 year study duration. |
Intravenous (IV) Infusion IV Infusion; IV Injection IV Infusion; IV Injection IV Infusion |
|
Experimental: Substudy 2: Dose Expansion Compatator
Participants will receive a fixed dose of FOLFOX and panitumumab as part of the approximately 6 year study duration. |
IV Infusion; IV Injection IV Infusion IV Infusion; IV Injection IV Infusion |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Objective Response (OR) as Assessed by the Investigator confirmed complete response (CR) or partial response (PR) as assessed by the investigator per response evaluation criteria in solid tumors (RECIST), version 1.1.
Periodo de tiempo: Up to 24 Weeks
|
OR is defined as confirmed CR or PR as assessed by the investigator per RECIST, version 1.1. |
Up to 24 Weeks
|
|
Number of Participants with Adverse Events (AE)s
Periodo de tiempo: Up to Approximately 6 Years
|
An adverse event is defined as any untoward medical occurrence in a participant or clinical investigation participant administered a pharmaceutical product and which does not necessarily have a causal relationship with this treatment. |
Up to Approximately 6 Years
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Progression-Free Survival (PFS) as Assessed by the Investigator
Periodo de tiempo: Up to 22 Months
|
PFS is defined as the time from the first dose of study treatment to the first occurrence of radiographic progression based on RECIST version 1.1 as determined by the investigator or death from any cause, whichever occurs earlier. |
Up to 22 Months
|
|
Duration of Response (DOR) as Assessed by the investigator
Periodo de tiempo: Up to 14 Months
|
DOR is defined as the time from the first documented CR or PR to the first occurrence of radiographic progression per RECIST v1.1 as determined by the investigator or death from any cause, whichever occurs first. |
Up to 14 Months
|
|
Overall Survival (OS)
Periodo de tiempo: Up to Approximately 6 Years
|
OS is defined as the time from first dose of study treatment to the event of death from any cause. |
Up to Approximately 6 Years
|
|
Disease Control (DC) as Assessed by the Investigator
Periodo de tiempo: Up to Approximately 6 Years
|
DC is defined as best overall response of confirmed CR or confirmed PR, or stable disease (SD) based on RECIST, version 1.1 as determined by the investigator. |
Up to Approximately 6 Years
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Director de estudio: ABBVIE INC., AbbVie
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Neoplasias por sitio
- Neoplasias
- Enfermedades intestinales
- Neoplasias Gastrointestinales
- Neoplasias del Sistema Digestivo
- Enfermedades del Sistema Digestivo
- Enfermedades Gastrointestinales
- Neoplasias Intestinales
- Enfermedades Rectales
- Enfermedades del Colon
- Neoplasias colorrectales
- Aminoácidos, péptidos y proteínas
- Proteínas
- Químicos orgánicos
- Compuestos heterocíclicos, 1 anillo
- Compuestos heterocíclicos
- Compuestos heterocíclicos, 2 anillos
- Compuestos heterocíclicos, anillo fusionado
- Enzimas y coenzimas
- Anticuerpos, monoclonales, humanizados
- Anticuerpos, monoclonal
- Anticuerpos
- Inmunoglobulinas
- Inmunoproteínas
- Proteínas de la sangre
- Globulinas séricas
- Globulinas
- Complejos de coordinación
- Pirimidinas
- Formiltetrahidrofolatos
- Tetrahidrofolatos
- Ácido fólico
- Pterins
- Pteridinas
- Uracílico
- Pirimidinonas
- Coenzimas
- Oxaliplatino
- Bevacizumab
- Panitumumab
- Fluorouracilo
- Leucovorina
Otros números de identificación del estudio
- M24-533
- EU CT (Otro identificador: 2024-512981-33-00)
- 2024-512981-33-00 (Ctis)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
AbbVie is committed to responsible clinical trial data sharing. This includes access to anonymized, individual and trial-level data (analysis data sets), as well as other information.
Marco de tiempo para compartir IPD
For details on when studies are available for sharing, visit https://vivli.org/ourmember/abbvie/
Criterios de acceso compartido de IPD
To learn more about the process, or to submit a request, visit the following link https://www.abbvieclinicaltrials.com/hcp/data-sharing/
Tipo de información de apoyo para compartir IPD
- PROTOCOLO DE ESTUDIO
- SAVIA
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
producto fabricado y exportado desde los EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .